ID   DYRK2_HUMAN             Reviewed;         601 AA.
AC   Q92630; B2R9V9; Q9BRB5;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   12-JUN-2007, sequence version 3.
DT   10-MAY-2017, entry version 177.
DE   RecName: Full=Dual specificity tyrosine-phosphorylation-regulated kinase 2;
DE            EC=2.7.12.1;
GN   Name=DYRK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, COFACTOR,
RP   PHOSPHORYLATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=9748265; DOI=10.1074/jbc.273.40.25893;
RA   Becker W., Weber Y., Wetzel K., Eirmbter K., Tejedor F.J.,
RA   Joost H.-G.;
RT   "Sequence characteristics, subcellular localization, and substrate
RT   specificity of DYRK-related kinases, a novel family of dual
RT   specificity protein kinases.";
RL   J. Biol. Chem. 273:25893-25902(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Muscle, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 320-528 (ISOFORMS 1/2).
RC   TISSUE=Placenta;
RA   Becker W., Joost H.-G.;
RL   Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   FUNCTION.
RX   PubMed=11311121;
RA   Woods Y.L., Cohen P., Becker W., Jakes R., Goedert M., Wang X.,
RA   Proud C.G.;
RT   "The kinase DYRK phosphorylates protein-synthesis initiation factor
RT   eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at
RT   Thr212: potential role for DYRK as a glycogen synthase kinase 3-
RT   priming kinase.";
RL   Biochem. J. 355:609-615(2001).
RN   [7]
RP   INDUCTION IN CANCER.
RX   PubMed=12874018;
RA   Miller C.T., Aggarwal S., Lin T.K., Dagenais S.L., Contreras J.I.,
RA   Orringer M.B., Glover T.W., Beer D.G., Lin L.;
RT   "Amplification and overexpression of the dual-specificity tyrosine-
RT   (Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and
RT   lung adenocarcinomas.";
RL   Cancer Res. 63:4136-4143(2003).
RN   [8]
RP   FUNCTION.
RX   PubMed=12588975; DOI=10.1128/MCB.23.5.1546-1557.2003;
RA   Wang X., Li W., Parra J.L., Beugnet A., Proud C.G.;
RT   "The C terminus of initiation factor 4E-binding protein 1 contains
RT   multiple regulatory features that influence its function and
RT   phosphorylation.";
RL   Mol. Cell. Biol. 23:1546-1557(2003).
RN   [9]
RP   FUNCTION.
RX   PubMed=14593110; DOI=10.1074/jbc.M301769200;
RA   Skurat A.V., Dietrich A.D.;
RT   "Phosphorylation of Ser640 in muscle glycogen synthase by DYRK family
RT   protein kinases.";
RL   J. Biol. Chem. 279:2490-2498(2004).
RN   [10]
RP   INTERACTION WITH CCNL2.
RX   PubMed=14623875; DOI=10.1074/jbc.M310794200;
RA   de Graaf K., Hekerman P., Spelten O., Herrmann A., Packman L.C.,
RA   Bussow K., Muller-Newen G., Becker W.;
RT   "Characterization of cyclin L2, a novel cyclin with an
RT   arginine/serine-rich domain: phosphorylation by DYRK1A and
RT   colocalization with splicing factors.";
RL   J. Biol. Chem. 279:4612-4624(2004).
RN   [11]
RP   FUNCTION.
RX   PubMed=15910284; DOI=10.1042/BJ20050733;
RA   Auld G.C., Campbell D.G., Morrice N., Cohen P.;
RT   "Identification of calcium-regulated heat-stable protein of 24 kDa
RT   (CRHSP24) as a physiological substrate for PKB and RSK using
RT   KESTREL.";
RL   Biochem. J. 389:775-783(2005).
RN   [12]
RP   FUNCTION AS CRMP4/DPYSL3 KINASE, AND ENZYME REGULATION BY PURVALANOL.
RX   PubMed=16611631; DOI=10.1074/jbc.M513344200;
RA   Cole A.R., Causeret F., Yadirgi G., Hastie C.J., McLauchlan H.,
RA   McManus E.J., Hernandez F., Eickholt B.J., Nikolic M., Sutherland C.;
RT   "Distinct priming kinases contribute to differential regulation of
RT   collapsin response mediator proteins by glycogen synthase kinase-3 in
RT   vivo.";
RL   J. Biol. Chem. 281:16591-16598(2006).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH NFATC1.
RX   PubMed=16511445; DOI=10.1038/nature04631;
RA   Gwack Y., Sharma S., Nardone J., Tanasa B., Iuga A., Srikanth S.,
RA   Okamura H., Bolton D., Feske S., Hogan P.G., Rao A.;
RT   "A genome-wide Drosophila RNAi screen identifies DYRK-family kinases
RT   as regulators of NFAT.";
RL   Nature 441:646-650(2006).
RN   [14]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17349958; DOI=10.1016/j.molcel.2007.02.007;
RA   Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K.;
RT   "DYRK2 is targeted to the nucleus and controls p53 via Ser46
RT   phosphorylation in the apoptotic response to DNA damage.";
RL   Mol. Cell 25:725-738(2007).
RN   [15]
RP   FUNCTION IN APOPTOSIS AS P53/TP53 KINASE, SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION BY ATM, AND GENE FAMILY.
RX   PubMed=18599021; DOI=10.1016/j.bcp.2008.05.021;
RA   Yoshida K.;
RT   "Role for DYRK family kinases on regulation of apoptosis.";
RL   Biochem. Pharmacol. 76:1389-1394(2008).
RN   [16]
RP   FUNCTION, AND PHOSPHORYLATION AT THR-381 AND SER-449.
RX   PubMed=18455992; DOI=10.1016/j.cell.2008.02.047;
RA   Varjosalo M., Bjorklund M., Cheng F., Syvanen H., Kivioja T.,
RA   Kilpinen S., Sun Z., Kallioniemi O., Stunnenberg H.G., He W.W.,
RA   Ojala P., Taipale J.;
RT   "Application of active and kinase-deficient kinome collection for
RT   identification of kinases regulating hedgehog signaling.";
RL   Cell 133:537-548(2008).
RN   [17]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18539531; DOI=10.1016/j.molmed.2008.05.003;
RA   Yoshida K.;
RT   "Nuclear trafficking of pro-apoptotic kinases in response to DNA
RT   damage.";
RL   Trends Mol. Med. 14:305-313(2008).
RN   [18]
RP   ENZYME REGULATION BY HARMINE.
RX   PubMed=19796173; DOI=10.1111/j.1742-4658.2009.07346.x;
RA   Goeckler N., Jofre G., Papadopoulos C., Soppa U., Tejedor F.J.,
RA   Becker W.;
RT   "Harmine specifically inhibits protein kinase DYRK1A and interferes
RT   with neurite formation.";
RL   FEBS J. 276:6324-6337(2009).
RN   [19]
RP   FUNCTION IN E3 LIGASE REGULATION, FUNCTION AS KATNA1 KINASE, AND
RP   INTERACTION WITH EDVP COMPLEX.
RX   PubMed=19287380; DOI=10.1038/ncb1848;
RA   Maddika S., Chen J.;
RT   "Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3
RT   ligase.";
RL   Nat. Cell Biol. 11:409-419(2009).
RN   [20]
RP   ENZYME REGULATION BY ACRIDINE ANALOGS.
RX   PubMed=20836251; DOI=10.1016/j.bmcl.2010.04.150;
RA   Cuny G.D., Robin M., Ulyanova N.P., Patnaik D., Pique V., Casano G.,
RA   Liu J.-F., Lin X., Xian J., Glicksman M.A., Stein R.L.,
RA   Higgins J.M.G.;
RT   "Structure-activity relationship study of acridine analogs as haspin
RT   and DYRK2 kinase inhibitors.";
RL   Bioorg. Med. Chem. Lett. 20:3491-3494(2010).
RN   [21]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-106 AND SER-442 BY ATM,
RP   UBIQUITINATION BY MDM2, INTERACTION WITH MDM2, MUTAGENESIS OF THR-106;
RP   SER-442 AND 189-LYS--ARG-191, NUCLEAR LOCALIZATION SIGNAL, AND
RP   INDUCTION BY DNA DAMAGE.
RX   PubMed=19965871; DOI=10.1074/jbc.M109.042341;
RA   Taira N., Yamamoto H., Yamaguchi T., Miki Y., Yoshida K.;
RT   "ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the
RT   apoptotic response to DNA damage.";
RL   J. Biol. Chem. 285:4909-4919(2010).
RN   [22]
RP   FUNCTION.
RX   PubMed=22307329; DOI=10.1172/JCI60818;
RA   Taira N., Mimoto R., Kurata M., Yamaguchi T., Kitagawa M., Miki Y.,
RA   Yoshida K.;
RT   "DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle
RT   progression in human cancer cells.";
RL   J. Clin. Invest. 122:859-872(2012).
RN   [23]
RP   FUNCTION, AND UBIQUITINATION BY SIAH2.
RX   PubMed=22878263; DOI=10.1093/jmcb/mjs047;
RA   Perez M., Garcia-Limones C., Zapico I., Marina A., Schmitz M.L.,
RA   Munoz E., Calzado M.A.;
RT   "Mutual regulation between SIAH2 and DYRK2 controls hypoxic and
RT   genotoxic signaling pathways.";
RL   J. Mol. Cell Biol. 4:316-330(2012).
RN   [24]
RP   FUNCTION, AND MUTAGENESIS OF LYS-251.
RX   PubMed=23362280; DOI=10.1074/jbc.M112.416792;
RA   Jung H.Y., Wang X., Jun S., Park J.I.;
RT   "Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT
RT   degradation.";
RL   J. Biol. Chem. 288:7252-7262(2013).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-30, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.28 ANGSTROMS) OF 146-552 IN COMPLEX WITH
RP   INDIRUBIN.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of dual-specificity tyrosine phosphorylation
RT   regulated kinase 2 (DYRK2) in complex with an indirubin ligand.";
RL   Submitted (JAN-2010) to the PDB data bank.
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 146-540 IN COMPLEX WITH
RP   LEUCETTAMINE DERIVATIVE, PHOSPHORYLATION AT TYR-382,
RP   AUTOPHOSPHORYLATION, ENZYME REGULATION, AND CATALYTIC ACTIVITY.
RX   PubMed=22998443; DOI=10.1021/jm301034u;
RA   Tahtouh T., Elkins J.M., Filippakopoulos P., Soundararajan M.,
RA   Burgy G., Durieu E., Cochet C., Schmid R.S., Lo D.C., Delhommel F.,
RA   Oberholzer A.E., Pearl L.H., Carreaux F., Bazureau J.P., Knapp S.,
RA   Meijer L.;
RT   "Selectivity, cocrystal structures, and neuroprotective properties of
RT   leucettines, a family of protein kinase inhibitors derived from the
RT   marine sponge alkaloid leucettamine B.";
RL   J. Med. Chem. 55:9312-9330(2012).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.36 ANGSTROMS) OF 146-552.
RX   PubMed=23665168; DOI=10.1016/j.str.2013.03.012;
RA   Soundararajan M., Roos A.K., Savitsky P., Filippakopoulos P.,
RA   Kettenbach A.N., Olsen J.V., Gerber S.A., Eswaran J., Knapp S.,
RA   Elkins J.M.;
RT   "Structures of Down syndrome kinases, DYRKs, reveal mechanisms of
RT   kinase activation and substrate recognition.";
RL   Structure 21:986-996(2013).
RN   [29]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-98; LEU-198; ASN-245; SER-295;
RP   GLN-451 AND TYR-455.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in the
CC       regulation of the mitotic cell cycle, cell proliferation,
CC       apoptosis, organization of the cytoskeleton and neurite outgrowth.
CC       Functions in part via its role in ubiquitin-dependent proteasomal
CC       protein degradation. Functions downstream of ATM and
CC       phosphorylates p53/TP53 at 'Ser-46', and thereby contributes to
CC       the induction of apoptosis in response to DNA damage.
CC       Phosphorylates NFATC1, and thereby inhibits its accumulation in
CC       the nucleus and its transcription factor activity. Phosphorylates
CC       EIF2B5 at 'Ser-544', enabling its subsequent phosphorylation and
CC       inhibition by GSK3B. Likewise, phosphorylation of NFATC1,
CC       CRMP2/DPYSL2 and CRMP4/DPYSL3 promotes their subsequent
CC       phosphorylation by GSK3B. May play a general role in the priming
CC       of GSK3 substrates. Inactivates GYS1 by phosphorylation at 'Ser-
CC       641', and potentially also a second phosphorylation site, thus
CC       regulating glycogen synthesis. Mediates EDVP E3 ligase complex
CC       formation and is required for the phosphorylation and subsequent
CC       degradation of KATNA1. Phosphorylates TERT at 'Ser-457', promoting
CC       TERT ubiquitination by the EDVP complex. Phosphorylates SIAH2, and
CC       thereby increases its ubiquitin ligase activity. Promotes the
CC       proteasomal degradation of MYC and JUN, and thereby regulates
CC       progress through the mitotic cell cycle and cell proliferation.
CC       Promotes proteasomal degradation of GLI2 and GLI3, and thereby
CC       plays a role in smoothened and sonic hedgehog signaling. Plays a
CC       role in cytoskeleton organization and neurite outgrowth via its
CC       phosphorylation of DCX and DPYSL2. Phosphorylates CRMP2/DPYSL2,
CC       CRMP4/DPYSL3, DCX, EIF2B5, EIF4EBP1, GLI2, GLI3, GYS1, JUN, MDM2,
CC       MYC, NFATC1, p53/TP53, TAU/MAPT and KATNA1. Can phosphorylate
CC       histone H1, histone H3 and histone H2B (in vitro). Can
CC       phosphorylate CARHSP1 (in vitro). {ECO:0000269|PubMed:11311121,
CC       ECO:0000269|PubMed:12588975, ECO:0000269|PubMed:14593110,
CC       ECO:0000269|PubMed:15910284, ECO:0000269|PubMed:16511445,
CC       ECO:0000269|PubMed:16611631, ECO:0000269|PubMed:17349958,
CC       ECO:0000269|PubMed:18455992, ECO:0000269|PubMed:18599021,
CC       ECO:0000269|PubMed:19287380, ECO:0000269|PubMed:22307329,
CC       ECO:0000269|PubMed:22878263, ECO:0000269|PubMed:23362280,
CC       ECO:0000269|PubMed:9748265}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:22998443}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:9748265};
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:9748265};
CC   -!- ENZYME REGULATION: Activated by autophosphorylation on the second
CC       tyrosine residue in the Tyr-X-Tyr motif in the activation loop.
CC       Inhibited by acridine analogs, purvalanol, and barely by harmine.
CC       Inhibited by leucettine and leucettine derivatives.
CC       {ECO:0000269|PubMed:16611631, ECO:0000269|PubMed:19796173,
CC       ECO:0000269|PubMed:20836251, ECO:0000269|PubMed:22998443}.
CC   -!- SUBUNIT: Component of an E3 ligase complex containing DYRK2,
CC       EDD/UBR5, DDB1 and DCAF1 (EDVP complex). Interacts directly with
CC       EDD/UBR5, DDB1 and DCAF1. Interacts with SIAH2 and MDM2. Interacts
CC       with MAP3K10 and NFATC1. May also interact with CCNL2.
CC       {ECO:0000269|PubMed:14623875, ECO:0000269|PubMed:16511445,
CC       ECO:0000269|PubMed:19287380, ECO:0000269|PubMed:19965871,
CC       ECO:0000269|PubMed:22998443, ECO:0000269|Ref.26}.
CC   -!- INTERACTION:
CC       Q9NR20:DYRK4; NbExp=3; IntAct=EBI-749432, EBI-3914009;
CC       Q13422:IKZF1; NbExp=3; IntAct=EBI-749432, EBI-745305;
CC       Q9BQD3:KXD1; NbExp=3; IntAct=EBI-749432, EBI-739657;
CC       Q9BRK4:LZTS2; NbExp=3; IntAct=EBI-749432, EBI-741037;
CC       P23497:SP100; NbExp=3; IntAct=EBI-749432, EBI-751145;
CC       O43379:WDR62; NbExp=3; IntAct=EBI-749432, EBI-714790;
CC       Q96C00:ZBTB9; NbExp=3; IntAct=EBI-749432, EBI-395708;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Translocates into
CC       the nucleus following DNA damage.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q92630-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q92630-2; Sequence=VSP_026115;
CC   -!- TISSUE SPECIFICITY: Testis, after the onset of spermatogenesis.
CC       {ECO:0000269|PubMed:9748265}.
CC   -!- INDUCTION: Accumulates in nucleus upon DNA damage. Induced in both
CC       esophageal and lung adenocarcinomas. {ECO:0000269|PubMed:12874018,
CC       ECO:0000269|PubMed:19965871}.
CC   -!- PTM: Autophosphorylates cotranslationally on the second tyrosine
CC       residue in the Tyr-X-Tyr motif in the activation loop, but once
CC       mature, does not have any protein tyrosine kinase activity.
CC       Phosphorylated at Thr-106 and Ser-442 by ATM in response to
CC       genotoxic stress. {ECO:0000269|PubMed:19965871}.
CC   -!- PTM: Under normal conditions, polyubiquitinated in the nucleus by
CC       MDM2, leading to its proteasomal degradation. Phosphorylation on
CC       Thr-106 and Ser-442 by ATM in response to genotoxic stress
CC       disrupts MDM2 binding and prevents MDM2-mediated ubiquitination
CC       and subsequent proteasomal degradation. Polyubiquitinated by
CC       SIAH2, leading to its proteasomal degradation. Polyubiquitinated
CC       by SIAH2 occurs under normal conditions, and is enhanced in
CC       response to hypoxia. {ECO:0000269|PubMed:19965871,
CC       ECO:0000269|PubMed:22878263}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. MNB/DYRK subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA73885.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y13493; CAA73885.1; ALT_INIT; mRNA.
DR   EMBL; AK313937; BAG36656.1; -; mRNA.
DR   EMBL; CH471054; EAW97176.1; -; Genomic_DNA.
DR   EMBL; BC005809; AAH05809.1; -; mRNA.
DR   EMBL; BC006375; AAH06375.1; -; mRNA.
DR   EMBL; Y09216; CAA70418.1; -; mRNA.
DR   CCDS; CCDS8978.1; -. [Q92630-1]
DR   CCDS; CCDS8979.1; -. [Q92630-2]
DR   RefSeq; NP_003574.1; NM_003583.3. [Q92630-2]
DR   RefSeq; NP_006473.2; NM_006482.2. [Q92630-1]
DR   RefSeq; XP_016875521.1; XM_017020032.1. [Q92630-2]
DR   UniGene; Hs.173135; -.
DR   PDB; 3K2L; X-ray; 2.36 A; A=146-552.
DR   PDB; 3KVW; X-ray; 2.28 A; A=146-552.
DR   PDB; 4AZF; X-ray; 2.55 A; A=146-540.
DR   PDB; 5LXC; X-ray; 2.15 A; A/B=146-552.
DR   PDB; 5LXD; X-ray; 2.58 A; A/B=146-552.
DR   PDBsum; 3K2L; -.
DR   PDBsum; 3KVW; -.
DR   PDBsum; 4AZF; -.
DR   PDBsum; 5LXC; -.
DR   PDBsum; 5LXD; -.
DR   ProteinModelPortal; Q92630; -.
DR   SMR; Q92630; -.
DR   BioGrid; 114023; 51.
DR   IntAct; Q92630; 12.
DR   MINT; MINT-1469581; -.
DR   STRING; 9606.ENSP00000342105; -.
DR   BindingDB; Q92630; -.
DR   ChEMBL; CHEMBL4376; -.
DR   GuidetoPHARMACOLOGY; 2011; -.
DR   iPTMnet; Q92630; -.
DR   PhosphoSitePlus; Q92630; -.
DR   BioMuta; DYRK2; -.
DR   DMDM; 148887370; -.
DR   EPD; Q92630; -.
DR   MaxQB; Q92630; -.
DR   PaxDb; Q92630; -.
DR   PeptideAtlas; Q92630; -.
DR   PRIDE; Q92630; -.
DR   DNASU; 8445; -.
DR   Ensembl; ENST00000344096; ENSP00000342105; ENSG00000127334. [Q92630-1]
DR   Ensembl; ENST00000393555; ENSP00000377186; ENSG00000127334. [Q92630-2]
DR   GeneID; 8445; -.
DR   KEGG; hsa:8445; -.
DR   UCSC; uc001str.5; human. [Q92630-1]
DR   CTD; 8445; -.
DR   DisGeNET; 8445; -.
DR   GeneCards; DYRK2; -.
DR   HGNC; HGNC:3093; DYRK2.
DR   HPA; HPA027230; -.
DR   HPA; HPA056902; -.
DR   MIM; 603496; gene.
DR   neXtProt; NX_Q92630; -.
DR   OpenTargets; ENSG00000127334; -.
DR   PharmGKB; PA27550; -.
DR   eggNOG; KOG0667; Eukaryota.
DR   eggNOG; ENOG410XPET; LUCA.
DR   GeneTree; ENSGT00760000119032; -.
DR   HOGENOM; HOG000220863; -.
DR   HOVERGEN; HBG051426; -.
DR   InParanoid; Q92630; -.
DR   KO; K18669; -.
DR   OMA; KLTTFEH; -.
DR   OrthoDB; EOG091G0Q46; -.
DR   PhylomeDB; Q92630; -.
DR   TreeFam; TF314624; -.
DR   BRENDA; 2.7.12.1; 2681.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   SignaLink; Q92630; -.
DR   SIGNOR; Q92630; -.
DR   ChiTaRS; DYRK2; human.
DR   EvolutionaryTrace; Q92630; -.
DR   GeneWiki; DYRK2; -.
DR   GenomeRNAi; 8445; -.
DR   PRO; PR:Q92630; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000127334; -.
DR   CleanEx; HS_DYRK2; -.
DR   ExpressionAtlas; Q92630; baseline and differential.
DR   Genevisible; Q92630; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030529; C:intracellular ribonucleoprotein complex; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000151; C:ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0043130; F:ubiquitin binding; IDA:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IEP:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB.
DR   GO; GO:0051534; P:negative regulation of NFAT protein import into nucleus; IMP:UniProtKB.
DR   GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0007224; P:smoothened signaling pathway; IMP:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Complete proteome; Cytoplasm; Kinase; Magnesium; Manganese;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Tyrosine-protein kinase; Ubl conjugation; Ubl conjugation pathway.
FT   CHAIN         1    601       Dual specificity tyrosine-
FT                                phosphorylation-regulated kinase 2.
FT                                /FTId=PRO_0000085936.
FT   DOMAIN      222    535       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     228    236       ATP. {ECO:0000305}.
FT   NP_BIND     301    304       ATP. {ECO:0000305}.
FT   MOTIF       189    191       Nuclear localization signal.
FT                                {ECO:0000305|PubMed:19965871}.
FT   ACT_SITE    348    348       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     251    251       ATP. {ECO:0000305}.
FT   MOD_RES      30     30       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     106    106       Phosphothreonine; by ATM.
FT                                {ECO:0000269|PubMed:19965871}.
FT   MOD_RES     381    381       Phosphothreonine; by MAP3K10.
FT                                {ECO:0000269|PubMed:18455992}.
FT   MOD_RES     382    382       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:22998443}.
FT   MOD_RES     442    442       Phosphoserine; by ATM.
FT                                {ECO:0000269|PubMed:19965871}.
FT   MOD_RES     449    449       Phosphoserine; by MAP3K10.
FT                                {ECO:0000269|PubMed:18455992}.
FT   VAR_SEQ       1     73       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_026115.
FT   VARIANT      98     98       S -> G (in dbSNP:rs35139851).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040458.
FT   VARIANT     198    198       P -> L (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040459.
FT   VARIANT     245    245       H -> N (in dbSNP:rs34166200).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040460.
FT   VARIANT     295    295       N -> S (in dbSNP:rs56293072).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040461.
FT   VARIANT     451    451       R -> Q (in dbSNP:rs35688869).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040462.
FT   VARIANT     455    455       F -> Y (in dbSNP:rs55774594).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040463.
FT   MUTAGEN     106    106       T->A: Impaired ATM-mediated
FT                                phosphorylation, reduced affinity with
FT                                MDM2 and altered MDM2-triggered
FT                                ubiquitination.
FT                                {ECO:0000269|PubMed:19965871}.
FT   MUTAGEN     189    191       KKR->NNN: Impaired nuclear translocation.
FT                                {ECO:0000269|PubMed:19965871}.
FT   MUTAGEN     251    251       K->R: Abolishes protein serine/threonine
FT                                kinase activity.
FT                                {ECO:0000269|PubMed:23362280}.
FT   MUTAGEN     442    442       S->A: Impaired ATM-mediated
FT                                phosphorylation, reduced affinity with
FT                                MDM2 and altered MDM2-triggered
FT                                ubiquitination.
FT                                {ECO:0000269|PubMed:19965871}.
FT   CONFLICT     37     37       A -> P (in Ref. 1; CAA73885).
FT                                {ECO:0000305}.
FT   STRAND      149    152       {ECO:0000244|PDB:3KVW}.
FT   HELIX       156    163       {ECO:0000244|PDB:5LXC}.
FT   HELIX       164    166       {ECO:0000244|PDB:5LXC}.
FT   HELIX       169    174       {ECO:0000244|PDB:5LXC}.
FT   HELIX       175    177       {ECO:0000244|PDB:5LXC}.
FT   STRAND      179    181       {ECO:0000244|PDB:3K2L}.
FT   HELIX       198    202       {ECO:0000244|PDB:5LXC}.
FT   STRAND      206    208       {ECO:0000244|PDB:3K2L}.
FT   TURN        219    221       {ECO:0000244|PDB:5LXC}.
FT   STRAND      222    231       {ECO:0000244|PDB:5LXC}.
FT   STRAND      234    241       {ECO:0000244|PDB:5LXC}.
FT   TURN        242    245       {ECO:0000244|PDB:5LXC}.
FT   STRAND      246    253       {ECO:0000244|PDB:5LXC}.
FT   HELIX       257    274       {ECO:0000244|PDB:5LXC}.
FT   STRAND      287    292       {ECO:0000244|PDB:5LXC}.
FT   STRAND      297    301       {ECO:0000244|PDB:5LXC}.
FT   HELIX       308    314       {ECO:0000244|PDB:5LXC}.
FT   TURN        315    317       {ECO:0000244|PDB:5LXC}.
FT   HELIX       322    341       {ECO:0000244|PDB:5LXC}.
FT   HELIX       351    353       {ECO:0000244|PDB:5LXC}.
FT   STRAND      354    358       {ECO:0000244|PDB:5LXC}.
FT   STRAND      364    366       {ECO:0000244|PDB:5LXC}.
FT   HELIX       375    377       {ECO:0000244|PDB:3K2L}.
FT   HELIX       386    388       {ECO:0000244|PDB:5LXC}.
FT   HELIX       391    395       {ECO:0000244|PDB:5LXC}.
FT   HELIX       402    417       {ECO:0000244|PDB:5LXC}.
FT   HELIX       427    438       {ECO:0000244|PDB:5LXC}.
FT   HELIX       443    447       {ECO:0000244|PDB:5LXC}.
FT   HELIX       452    455       {ECO:0000244|PDB:5LXC}.
FT   STRAND      465    469       {ECO:0000244|PDB:5LXC}.
FT   STRAND      471    473       {ECO:0000244|PDB:5LXC}.
FT   STRAND      475    478       {ECO:0000244|PDB:5LXC}.
FT   HELIX       496    499       {ECO:0000244|PDB:5LXC}.
FT   TURN        500    502       {ECO:0000244|PDB:5LXC}.
FT   HELIX       506    515       {ECO:0000244|PDB:5LXC}.
FT   TURN        520    522       {ECO:0000244|PDB:5LXC}.
FT   HELIX       526    529       {ECO:0000244|PDB:5LXC}.
FT   HELIX       533    535       {ECO:0000244|PDB:5LXC}.
SQ   SEQUENCE   601 AA;  66652 MW;  A7BEE25CDF944436 CRC64;
     MLTRKPSAAA PAAYPTGRGG DSAVRQLQAS PGLGAGATRS GVGTGPPSPI ALPPLRASNA
     AAAAHTIGGS KHTMNDHLHV GSHAHGQIQV QQLFEDNSNK RTVLTTQPNG LTTVGKTGLP
     VVPERQLDSI HRRQGSSTSL KSMEGMGKVK ATPMTPEQAM KQYMQKLTAF EHHEIFSYPE
     IYFLGLNAKK RQGMTGGPNN GGYDDDQGSY VQVPHDHVAY RYEVLKVIGK GSFGQVVKAY
     DHKVHQHVAL KMVRNEKRFH RQAAEEIRIL EHLRKQDKDN TMNVIHMLEN FTFRNHICMT
     FELLSMNLYE LIKKNKFQGF SLPLVRKFAH SILQCLDALH KNRIIHCDLK PENILLKQQG
     RSGIKVIDFG SSCYEHQRVY TYIQSRFYRA PEVILGARYG MPIDMWSLGC ILAELLTGYP
     LLPGEDEGDQ LACMIELLGM PSQKLLDASK RAKNFVSSKG YPRYCTVTTL SDGSVVLNGG
     RSRRGKLRGP PESREWGNAL KGCDDPLFLD FLKQCLEWDP AVRMTPGQAL RHPWLRRRLP
     KPPTGEKTSV KRITESTGAI TSISKLPPPS SSASKLRTNL AQMTDANGNI QQRTVLPKLV
     S
//
